Home
NICE Guidance
Conditions and diseases
Urological conditions
Bladder cancer
Show sections
3 new
and
0 updated
products since January 2017.
NICE Pathways - mapping our guidance
Bladder cancer
Lung cancer
Prostate cancer
Renal cancer
Suspected cancer recognition and referral
Quality standards
Bladder cancer
(QS106)
December 2015
Suspected cancer
(QS124)
June 2016
NICE
Guidelines
Bladder cancer: diagnosis and management
(NG2)
February 2015
Improving outcomes in urological cancers
(CSG2)
September 2002
Suspected cancer: recognition and referral
(NG12)
June 2015
Interventional procedures guidance
Electrically-stimulated intravesical chemotherapy for superficial bladder cancer
(IPG277)
November 2008
Intravesical microwave hyperthermia with intravesical chemotherapy for superficial bladder cancer
(IPG235)
October 2007
Laparoscopic cystectomy
(IPG287)
February 2009
Technology appraisal guidance
Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract
(TA272)
January 2013
In development
Atezolizumab for treating metastatic urothelial bladder cancer after platinum-based chemotherapy [ID939]
(GID-TA10111)
TBC
Technology appraisal guidance
Nivolumab for treating metastatic or unresectable urothelial cancer after platinum-based chemotherapy [ID995]
(GID-TA10163)
February 2018
Technology appraisal guidance
Pembrolizumab for urothelial cancer [ID1019]
(GID-TA10113)
November 2017
Technology appraisal guidance
Guidance
Resources
Savings and productivity
Local practice